Beyond Ranbaxygate: trust, mistrust and Indian generics
This article was originally published in Scrip
Executive Summary
Okay, first things first. This isn't about a patriotic defense of any defrauding company, even if it is the once iconic Ranbaxy Laboratories. This also isn't about taking anything away from the courageous whistleblower, Dinesh Thakur, a former director and global head, research information and portfolio management at the firm, who exposed the rot in the now Daiichi Sankyo-controlled company and helped the US FDA and Department of Justice unravel a complicated trail of falsified records and manufacturing practices that violated GMP norms.